Edition:
United Kingdom

Aurobindo Pharma Ltd (ARBN.NS)

ARBN.NS on National Stock Exchange of India

667.60INR
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
Rs667.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,537,522
52-wk High
Rs809.45
52-wk Low
Rs503.05

Select another date:

Thu, Nov 9 2017

Aurobindo Pharma Q2 profit rises 29 pct, beats estimates

Nov 9 India's Aurobindo Pharma Ltd posted a better-than-expected 29 percent rise in quarterly profit on Thursday, helped by higher sales at its formulations business in the United States.

BRIEF-Aurobindo Pharma gets U.S. FDA nod for esomeprazole magnesium DR capsules OTC

* Says ‍received final approval from U.S. FDA to manufacture esomeprazole magnesium delayed-release capsules OTC, 20mg​

BRIEF-Aurobindo Pharma gets USFDA approval for drugs used for treatement of HIV-1 infection

* Receives USFDA tentative approval for Dolutegravir, Lamivudine & Tenofovir Disoproxil Fumarate tablets

UPDATE 1-Aurobindo Pharma Q1 profit drops 11 pct, misses estimates

Aug 9 Indian drugmaker Aurobindo Pharma Ltd reported a 11 percent fall in quarterly profit, hurt by lower sales from its formulations business in the U.S. and pre-launch disruptions of a pan-India tax reform.

BRIEF-India's Aurobindo Pharma June-qtr consol profit down about 11 pct

* June quarter consol net profit 5.19 billion rupees versus 5.85 billion rupees last year

Indian shares close higher; Aurobindo Pharma leads

July 19 Indian shares recovered on Wednesday as cigarette maker ITC rebounded and drugmakers gained on hopes of U.S. regulatory approvals and the launches of new drugs.

BRIEF-Aurobindo Pharma gets USFDA approval for Sevelamer Carbonate tablets

* Says Aurobindo Pharma receives USFDA approval for Sevelamer Carbonate tablets

Select another date: